MAGE-A10 TCR

N/A

Report date: 2026/03/17 20:00:15

Base Information

Drug NameMAGE-A10 TCR
Drug Alias NameMelanoma-associated antigen A10-specific T-cellsMAGE-A10 SPEAR T-cell therapyMAGE A10-specific T-cellsMAGE A10-transduced lymphocytesMAGE A-10 TCR +[10] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionMelanoma-associated antigen 10 modulatorsGene transference
TargetsMelanoma-associated antigen 10
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsCarcinoma, Transitional Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdaptimmune Llc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsCarcinoma, Transitional Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A